Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
47 hedge funds and large institutions have $165M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
62% more capital invested
Capital invested by funds: $102M → $165M (+$62.9M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% less funds holding
Funds holding: 51 → 47 (-4)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$8.19M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.84M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.64M |
| 4 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$1.46M |
| 5 |
O
OrbiMed
New York
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.5M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$2.79M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.29M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$396K |
THRX Hedge Fund Activity: Q4 2022 in Review
47 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q4 2022, worth a combined $165M — up 62% from $102M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of THRX and 4 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 20 added.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $8.19M. The largest seller was Fidelity Investments, cutting an estimated $13.5M.
- 47 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q4 2022, down from 51 in Q3 2022.
- Funds reported $165M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q4 2022, up 62% quarter-over-quarter.
- 4 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 7 closed out, a net change of -3 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Frazier Life Sciences Management, an estimated $8.19M added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was Fidelity Investments, an estimated $13.5M sold.
Based on aggregated 13F filings for Q4 2022.